期刊
ANTIVIRAL RESEARCH
卷 81, 期 2, 页码 180-183出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2008.09.004
关键词
Hepatitis B virus; Entecavir; Antiviral therapy; Drug resistance; Quasi-species evolution
资金
- National High Technology Research Development Program of China [2007AA02Z494]
- National Natural Science Foundation of China [30400377]
The genotypic evolution of HBV quasi-species was analyzed in a nucleoside/nucleotide-naive patient who developed resistance to entecavir. The lamivudine resistant quasi-species (rtM204V +/- rtL180M), absent at baseline, were emerged as early as 48 weeks after entecavir administration. Entecavir-resistant quasi-species (rtM204V +/- rtL180M plus S202G) were found after week 112 and gradually became the predominant mutations afterwards. The lamivudine- and entecavir-resistant mutations emerged closely in combination with the rtV207L, rtA222T, rtP237T or rtI163V substitutions. Our results indicated that the lamivudine-resistant mutations were developed first and may serve as a prequisite for subsequent entecavir-resistant mutations in this nucleoside/nucleotide-naive patient. (C) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据